I am a practicing Urological Pathologist at the Beth Israel Deaconess Medical Center. My main research interest is to study molecular characteristics of aggressive prostate cancer, to distinguish them from indolent ones, with an ultimately goal to increase early detection and treatment of aggressive prostate cancer and to improve management of patients with indolent cancer. In collaboration with Dr. Steven Balk, one of my main projects is to identify genetic characteristics of different Gleason grades of prostate cancer and to study molecular mechanisms of progression from low to high grade cancer. A related project of mine is to study prognostic values of potential biomarkers for Gleason upgrading in active surveillance patients. In addition, I study androgen receptor signaling and resistant mechanisms in high risk prostate cancer in neoadjuvant clinical trials that patients are treated with combined Lupron and abiraterone and/or enzalutamide prior to radical prostatectomy. Revealing alternative androgen receptor signaling and other resistant mechanisms in the residual tumors will shed light on how to select sensitive patients for neoadjuvant androgen deprivation therapy and provide new drug targets for potential cure.